"Quite decent progress" is how executive chairman Stuart Sim describes ML's performance. In the past year, ML has completed its disposal programme, raised GBP14.4m in a rights issue that could see it through to profitability if hoped-for milestone payments come through, and successfully placed the overhanging share stake held by bankrupt ex-chairman Kevin Leech.
ML has also signed a flurry of licensing deals. Its respiratory division, Innovata Biomed, licensed its C200 inhaler to an undisclosed European pharmaceutical firm and its Budesonide…
